Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC

This study tests whether adding a drug called trilaciclib (which protects bone marrow during chemotherapy) to a standard chemotherapy called docetaxel helps people with advanced (Stage IV) non-small cell lung cancer (NSCLC) who have already received prior treatment. **You may be eligible if...** - You are 18 years or older - You have Stage IV NSCLC that has not responded to or has progressed after at least one standard treatment - You have at least one measurable tumor - Your blood counts and organ function meet required levels - You are in reasonably good health **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your cancer has not previously been treated with standard first-line therapy - Your organ function (liver, kidney, blood) does not meet required thresholds - You have an expected survival of less than 3 months Talk to your doctor to see if this trial is right for you.